Optibiotix Health Share Discussion Threads

[parob] 08/1/2019 14:25

Investors holding out for much bigger gains.97.8p for very small amounts currently.

[onedayrodders] 08/1/2019 14:17

Very encouraging to see the relentless 10, 20 and 30k sales disappear.

Let's hope it's not temporary

[rafboy] 08/1/2019 14:11

Come on everybody, heave!

[nobbygnome] 08/1/2019 14:01

Only Finncap left on the 98p offer!

[nobbygnome] 08/1/2019 13:59

I wilł blame you personally dazah if I don't make money on them 😜

97p offer has gone...

[dazah] 08/1/2019 13:57

You're a good man Nobby! Well done :)

[parob] 08/1/2019 13:57

Just seen your 5K on nex Nobby at 96.7p. I guess we might be through 100p by the end of week at this rate. Once through get ready for the technical traders to pile in.

[judijudi] 08/1/2019 13:53

Nice one nobby

[nobbygnome] 08/1/2019 13:47

Ok in for my very last 5k just for dazah! Level 2 is looking good for a further rise.

[judijudi] 08/1/2019 13:35

Its when he advises his followers to sell (and he himself sells some) that will cause the price to drop
As it did last time

[trotterstrading] 08/1/2019 13:21

He will lift his buy price soon IMO, probably waiting for the blockbuster RNS

[primal123] 08/1/2019 13:20

Yes agree, think we will get a trading update and not a deal with numbers!

[scotty1] 08/1/2019 13:16

dazah stop talking silly.All tipsters have buying and selling targets it doesn't necessarily mean it'll get to that target or that it wont fly past that target.

[scotty1] 08/1/2019 13:13

risky TW actually said announcements with hard numbers attached in the coming weeks, that could mean in the form of a trading statement.

[dazah] 08/1/2019 13:12

What's TW now saying to buy up to? 90p still?? No point buying opti at this price eh? Too high according to TW.

[riskybusiness1] 08/1/2019 13:05

'Deals with hard numbers' is a pointless phrase. considering how these sales are generated I think a deal with hard numbers is not possible unless a specific annual milestone payment or MOQ is agreed with a large partner. Even then Opti are not going to want to put a price on a deal as this immediately sets a ceiling price from which to negotiate further deals with other partners. I'm pretty sure SOH mentioned putting out a trading statement early this year in recent interviews showing the jump in revenues in H2 last year.

[parob] 08/1/2019 12:59

Chis chap is connected with SOH and Christina on LinkedIn – his status update yesterday:Subendu Kumar BrahmaSenior Manager - Business Development with Zeon Lifesciences Ltd Zeon Lifesciences Ltd; Noida (India) Signed an Exclusive Agreement with OptiBiotix Health Plc; York (UK) for In -Licensing of Branded Ingredient SlimBiome® for India & Southern Asia SLIMBIOME®: An Award-Winning Weight Management Product Backed by Science & Which Help Curb Food Cravings Independent clinical studies have shown that consumers who took SlimBiome®: Feel fuller and are less hungry; Experience fewer food cravings; Change their food choice to eat less sweet and fatty foods. The food industry has recognized the uniqueness of SlimBiome® with the two industry awards: Weight Management Ingredient of the Year (Vitafoods Europe 2018) and Best Functional Ingredient for Health and Well Being (Food Matters 2017). Please Contact us at [e-mail] for Launching the Final Product in Indian Market

[primal123] 08/1/2019 12:54

Yes we will just have to wait and see, but I definitely think we are going to get something with numbers soon!

[scotty1] 08/1/2019 12:48

Primal in the update he does state he was chatting with SoH earlier,now whether that included deals with hard numbers attached is another question.

[primal123] 08/1/2019 12:44

Yes we hopefully will get a trading update. But when I asked SOH about comments he has made before like this he has said he knows the same as all the other investors and doesn't know where he got that from! I think we will get something, now is the time to invest for those waiting on sidelines!

[scotty1] 08/1/2019 12:42

someuwin what good news finally ? thought we'd had good news all the way down the line.

[bioking] 08/1/2019 12:40

OT) Look at Futura Medical (FUM) has a dirt low market cap of 19 Million and has 3 Drugs including a potential MEGA Blockbuster in Phase 3 for the treatment of erectile dysfunction which works way faster than market leaders like Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM stock alreay exploding higher thank me later .good luck all


Research Confirms MED2002's US$1 Billion Potential
hxxps://futuramedical.com/content/news/archive17/060317b.asp

The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time.

Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life.

The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development.

The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action.

The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts.


Pipeline
hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg

MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp

first patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

CSD500: Erectogenic condom
hxxps://futuramedical.com/content/products/csd_500.asp

Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets.

Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp

TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018.
Out-licensing discussions for TPR100 outside of the UK are ongoing.

[someuwin] 08/1/2019 12:40

EDIT: wrong board.

[scotty1] 08/1/2019 12:39

Very true Primal,but we must be very near to those hard numbers now.

[primal123] 08/1/2019 12:37

Scotty - he's been saying this for years lol he is going to get it right one time!